November 24, 2006 -- Schering won Australian approval for an expanded indication of multiple sclerosis drug Betaferon; Angiomax, an anti-clotting drug from the Medicines Company, was touted for acute coronary syndromes in a journal article; and Immunogen continued to trade higher after receiving an analyst Buy rating. The Centient Biotech 200™ was 7 points lower at 3985. More details...
